ImmunityBio Stock Surges for Tenth Straight Day on Revenue Jump
ImmunityBio shares rose 30.79% Thursday, marking a 10-day rally after reporting a 700% increase in preliminary 2025 revenue for its drug Anktiva.
Topic
Latest reporting and analysis tagged with ImmunityBio.
ImmunityBio shares rose 30.79% Thursday, marking a 10-day rally after reporting a 700% increase in preliminary 2025 revenue for its drug Anktiva.